Catalyst Pharmaceuticals, Inc. CPRX
Jul 15, 2026, 9:30 AM EDT
52-week range unavailable
- YTD
- +34.92%
- 1 year
- +43.86%
- Market cap
- 3.85B
- Profit margin
- 37.08%
- YTD return
- +34.92%
- 1-year return
- +43.86%
- Open
- 31.49
- Previous close
- 31.49
- Day's range
- 31.49 – 31.49
- Earnings date
- Aug 5, 2026
Key statistics
- Enterprise value
- 3.10B
- PEG ratio
- 2.07
- Price / sales
- 0.00
- Price / book
- 3.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 23.65%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.48 | — | — | — |
| May 11, 2026 | Mar 31, 2026 | 0.64 | 0.52 | -0.12 | -18.75% |
| Feb 25, 2026 | Dec 31, 2025 | 0.42 | 0.42 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | 0.51 | 0.43 | -0.08 | -15.69% |
| Aug 6, 2025 | Jun 30, 2025 | 0.58 | 0.43 | -0.15 | -25.86% |
| May 7, 2025 | Mar 31, 2025 | 0.53 | 0.47 | -0.06 | -11.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| May 8, 2026 | Citigroup | down | Buy | Neutral |
| May 7, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
| Mar 3, 2026 | Citigroup | main | Buy | Buy |
| Nov 7, 2025 | Citigroup | main | Buy | Buy |
| Mar 3, 2025 | Baird | main | Outperform | Outperform |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 182
- Website
- catalystpharma.com
News
Solaris Energy Infrastructure To Replace Catalyst Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On July 15, 2026 
Earnings Scheduled For May 11, 2026 
Deal Dispatch: J.M. Smucker Considers Strategic Review, Meta Buys Assured Robot Intelligence, Buzzfeed On Brink Of Bankruptcy 
12 Health Care Stocks Moving In Friday's After-Market Session - Earnings Scheduled For February 25, 2026
Jim Cramer: Crane Is A 'Good' Company, Recommends Holding This Tech Stock 
Earnings Scheduled For November 5, 2025 
Earnings Scheduled For August 6, 2025 
Top 3 Health Care Stocks You'll Regret Missing This Quarter 
Earnings Scheduled For May 7, 2025
Your note
Sign in to keep a note on CPRX — it syncs with the Stock Master app.